ConferenceJournal of Clinical Oncology · June 1, 2026
e12754Background:
Despite widespread adoption of the 21-gene Recurrence Score (Oncoty ...
Full textCite
ConferenceClinical Cancer Research · June 13, 2025
AbstractBackground: Breast cancer is increasingly prevalent in women over 65, and most are diagnosed with hormone receptor positive disease. While younger patients with early-stage breast cancer are treated ...
Full textCite
ConferenceClinical Cancer Research · June 13, 2025
AbstractBackground: Young women with early-stage breast cancer are increasingly choosing contralateral prophylactic mastectomy (CPM) despite longstanding data demonstrating that breast conservation is equall ...
Full textCite
ConferenceClinical Cancer Research · June 13, 2025
AbstractBackground: Neoadjuvant systemic therapy has emerged as the standard of care for many patients with breast cancer potentially leading to surgical downstaging and providing insight into treatment resp ...
Full textCite
ConferenceJournal of Clinical Oncology · June 1, 2025
e13116Background: Breast cancer is the most common malignancy among women and a major cause of cancer death. About 5-10% of breast cancer patients are initially diagnosed with stage IV (de novo metastatic breast cancer). A significant survival difference e ...
Full textCite
ConferenceCancer Research · April 25, 2025
AbstractBackground:The synergistic effects of radiotherapy (RT) and immunotherapy (IT) in cancer treatment have been increasingly reco ...
Full textCite
ConferenceCancer · January 1, 2025
BACKGROUND: This study compared incident breast cancer cases in the National Cancer Database (NCDB) and Surveillance, Epidemiology, End Results Program (SEER) to a national population cancer registry. METHODS: Patients with malignant or in situ breast canc ...
Full textLink to itemCite
ConferenceAnn Surg Oncol · December 2024
BACKGROUND: Axillary management after neoadjuvant chemotherapy (NAC) is evolving but axillary lymph node dissection (ALND) remains the standard of care for patients with residual nodal disease. The results of the Alliance A011202 trial evaluating the oncol ...
Full textLink to itemCite
ConferenceAnn Surg Oncol · November 2024
BACKGROUND: Patients with inflammatory breast cancer (IBC) have worse survival compared with stage III non-IBC matched cohorts; however, the prognostic significance of achieving pathologic complete response (pCR) in the setting of IBC is not well described ...
Full textLink to itemCite
ConferenceCancer Research · May 2, 2024
AbstractBackground: Women with breast cancer and a BRCA1 mutation face a high risk of contralateral breast cancer. For this reason, many women with a unilateral breast cancer opt for bilateral mastectomies. ...
Full textCite
ConferenceCancer Research · May 2, 2024
AbstractBackground Current American Joint Committee on Cancer (AJCC) breast cancer staging considers contralateral axillary metastasis (CAM) stage IV disease (M1). Retrospective studies suggest that women wi ...
Full textCite
ConferenceCancer Research · May 2, 2024
AbstractBackgroundGiven the heterogeneity in outcomes for de novo metastatic breast cancer (dnMBC), a staging system was recently developed that refines prognostic estimates ...
Full textCite
ConferenceCancer Research · May 2, 2024
AbstractBackgroundThe largest U.S. tumor registries, NCDB (National Cancer Database) and SEER (Surveillance, Epidemiology, and End Results Program), are vital sources of epid ...
Full textCite
ConferenceCancer Research · May 2, 2024
AbstractRadiation Therapy Toxicities and Survival Outcomes in Monoallelic ATM Variant Carriers with Non-Metastatic Breast Cancer: A Retrospective Analysis Rayan Bensenane1 MD, Arnaud Beddok1,2,3 MD, Nadine A ...
Full textCite
ConferenceJournal of Clinical Oncology · June 1, 2023
6512 Background: National tumor registries, such as the NCDB (National Cancer Database) and SEER (Surveillance, Epidemiology, and End Results Program), have been used to explore numerous research questions related to trends in di ...
Full textCite
ConferenceJournal of Clinical Oncology · June 1, 2023
6584 Background: Studies have shown that a low (<11) Oncotype DX recurrence score (RS) is associated with better survival outcomes. RS is currently included in the AJCC prognostic staging criteria. Not all patients with a low ...
Full textCite
ConferenceCancer Research · March 1, 2023
AbstractBackground: The predictive and prognostic value of the 21-gene recurrence score (RS) has emphasized the importance of tumor biology and minimized the credence of a limited (1-3 positive) nodal burden ...
Full textCite
ConferenceCancer Research · March 1, 2023
AbstractIntroduction: Despite the recent overall improvement in survival for patients with breast cancer, racial disparities in outcomes persist. While studies have demonstrated that socioeconomic factors an ...
Full textCite
ConferenceAm J Surg · January 2023
BACKGROUND: We investigated whether tumor phenotype influences surgical decision-making, and how that may impact overall survival (OS) for early-stage breast cancer. METHODS: Women aged 18-69 with cT0-2/cN0/cM0 breast cancer in the National Cancer Database ...
Full textLink to itemCite
ConferenceAnn Surg Oncol · October 2022
BACKGROUND: Multiple studies have demonstrated a link between obesity and breast cancer; however, the potential association between obesity and atypical high-risk breast lesions has not been well characterized. We sought to evaluate the characteristics and ...
Full textLink to itemCite
ConferenceJ Surg Oncol · May 2022
BACKGROUND: Malignant phyllodes (MP) and primary breast sarcomas (PBS) are rare neoplasms with overlapping histopathologic features. We compared overall survival (OS) and estimated the association of surgery and therapies with OS. METHODS: We utilized the ...
Full textLink to itemCite
ConferenceCancer · March 1, 2022
BACKGROUND: Asian women with breast cancer are often studied in aggregate, belying significant intragroup diversity. The authors sought to examine differences in breast cancer characteristics and outcomes among Asian women. METHODS: Asian, non-Hispanic Bla ...
Full textLink to itemCite
ConferenceAnn Surg Oncol · November 2021
BACKGROUND: Although metastatic breast cancer (MBC) remains incurable, advances in therapies have improved survival. Using a contemporary dataset of de novo MBC patients, we explore how overall (OS) and cancer-specific survival (CSS) changed over time. MET ...
Full textLink to itemCite
ConferenceAnn Surg Oncol · October 2021
BACKGROUND: Breast surgery carries a low risk of postoperative mortality. For older patients with multiple comorbidities, even low-risk procedures can confer some increased perioperative risk. We sought to identify factors associated with postoperative mor ...
Full textLink to itemCite
ConferenceAnn Surg Oncol · October 2021
BACKGROUND: Contralateral axillary nodal metastases (CAM) is classified as stage IV disease, although many centers treat CAM with curative intent. We hypothesized that patients with CAM, treated with multimodality therapy, would have improved overall survi ...
Full textLink to itemCite
ConferenceCancer · July 15, 2021
BACKGROUND: The North Carolina Breast and Cervical Cancer Control Program (NC BCCCP) provides breast cancer screening services to underserved women to mitigate disparities in access to care. The authors sought to characterize this understudied population. ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · May 20, 2021
1095 Background: Treatments for metastatic breast cancer (MBC) have significantly improved survival for patients who receive treatment, yet data describing the prognosis for untreated patients is lacking. Therefore, we sought to ...
Full textCite
ConferenceCancer Research · February 15, 2020
AbstractBackground: Meta-analyses have demonstrated that young women ≤40 (YW) derive the most benefit from chemotherapy (EBCTCG, Lancet. 1998). Oncotype DX was designed to determine the benefit of chemothera ...
Full textCite
ConferenceCancer Research · February 15, 2020
AbstractBackground: Guideline-concordant care (GCC) for DCIS includes surgery, radiation, and endocrine treatment. Active surveillance (AS) is a strategy under study for management of low risk DCIS. The PORT ...
Full textCite
ConferenceBreast Cancer Res Treat · February 2020
PURPOSE: National guidelines define adequate axillary lymph node dissections as those yielding ≥ 10 lymph nodes (LNs). We aimed to identify the optimal LN yield among node-positive patients. METHODS: Using the National Cancer Data Base (2010-2015), we cate ...
Full textLink to itemCite
ConferenceBreast Cancer Res Treat · February 2020
BACKGROUND: Given presumed differences in disease severity between young (≤ 45 years) and elderly (≥ 75 years) women with breast cancer, we sought to compare tumor histopathology, stage at presentation, patterns of care, and survival at the extremes of age ...
Full textLink to itemCite
ConferenceAm J Surg · October 2019
BACKGROUND: Sentinel lymph node biopsy has supplanted axillary lymph node dissection (ALND) in clinically node-negative breast cancer and select node-positive disease. We hypothesized a decreasing rate of both ALND and resident exposure over time. METHODS: ...
Full textLink to itemCite
ConferenceAnn Surg Oncol · October 2019
BACKGROUND: Ductal carcinoma in situ (DCIS) with microinvasion (DCISM) can be challenging in balancing the risks of overtreatment versus undertreatment. We compared DCISM, pure DCIS, and small volume (T1a) invasive ductal carcinoma (IDC) as related to hist ...
Full textLink to itemCite
ConferenceAnn Surg Oncol · October 2019
BACKGROUND: Neoadjuvant chemotherapy (NACT) is often recommended for patients with node-positive invasive lobular carcinoma (ILC) despite unclear benefit in this largely hormone receptor-positive (HR+) group. We sought to compare overall survival (OS) betw ...
Full textLink to itemCite
ConferenceCancer Research · February 15, 2019
AbstractBackground: BRCA mutated (BRCA+) breast cancers are expected to have increased activation of Homologous Recombination Deficiency (HRD) and altered DNA damage repair pathways when compared to BRCA wil ...
Full textCite
ConferencePsychooncology · February 2019
OBJECTIVE: Women with unilateral, early-stage breast cancer and low genetic risk are increasingly opting for contralateral prophylactic mastectomy (CPM), a concerning trend because CPM offers few clinical benefits while increasing risks of surgical complic ...
Full textLink to itemCite
ConferenceAnn Surg Oncol · October 2018
BACKGROUND: Recent studies suggest that surgical lymph node (LN) evaluation may be omitted in select elderly breast cancer patients as it may not influence adjuvant therapy decisions. To evaluate differences in adjuvant therapy receipt and overall survival ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · March 1, 2018
152 Background: More women with early-stage unilateral breast cancer and low genetic risk are opting for CPM, despite their low risk of developing cancer in their healthy breast and evidence to demonstrate that CPM improves neith ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2017
532 Background: Metaplastic breast cancer (MBC) is a rare, aggressive variant that is often triple negative (TN). Current guidelines recommend use of standard receptor-based treatment for MBC despite evidence of chemoresistance. ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2017
1570 Background: Metaplastic breast cancer (MBC) is a rare, aggressive, sarcomatoid breast cancer that was first described in 1973 but only became recognized as a histologically distinct entity in 2000. Given the paucity of data ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2017
e18144 Background: Breast oncologists have little guidance on predicting long term outcomes after interval survival. We aim to evaluate the association of overall survival (OS) with select factors at multiple time points. Methods ...
Full textCite
ConferenceCancer Research · May 1, 2015
AbstractIntroduction: With a reported incidence of 2-12% in breast biopsy specimens, the appropriate management of atypical ductal hyperplasia (ADH) remains in evolution. At present, the optimal screening gu ...
Full textCite
ConferenceJournal of Clinical Oncology · September 20, 2012
60 Background: Standard follow-up imaging for women with a history of breast cancer is well defined, but the appropriate screening guidelines for other high risk breast lesions, such as atypical ductal hyperplasia (ADH), remain u ...
Full textCite
ConferenceAm Surg · March 2005
Early postoperative oral feeding has been demonstrated to be safe and not increase postoperative morbidity. There are conflicting reports about its effect on postoperative length of stay. Some patients will fail attempts at early postoperative feeding and ...
Link to itemCite
https://orcid.org/0000-0002-7411-0558